Keywords: Osteonecrosis of the jaw; Medication-related osteonecrosis of the jaw; Bisphosphonate-related osteonecrosis of the jaw; Antiresorptive therapy; Preventive measures; Plasma-rich in growth factors; Extraction; Cancer patients; MRONJ; medication-related oste
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: BMs; bone metastases; BPI; Brief Pain Inventory; BTA; bone-targeted agent; CI; confidence interval; DSP; Disease Specific Programme; EQ-5D; 5-dimension (3-level) EuroQol questionnaire; ER; estrogen receptor; FACT-B; Functional Assessment of Cancer Therapy
Keywords: necrosis of the jaw; BRONJ; DRONJ; MRONJ; ONJ; bisphosphonate; osteonecrosis; bone fluorescence; tetracycline; auto-fluorescence; therapy; bone; VELscope;
Keywords: BMP; bone morphogenetic protein; c-Fms; colony-stimulating factor-1 receptor; CSF-1; colony-stimulating factor-1; GM-CSF; granulocyte-macrophage colony-stimulating factor; HSCs; hematopoietic stem cells; IL; interleukin; LPS; lipopolysaccharides; MAFIA; m
Keywords: Bisphosphonates; Denosumab; Antiremodeling agents; ONJ;
Keywords: RANKL-inhibitor; Xgeva; Denosumab; Osteonecrosis of the jaw; ONJ; Bisphosphonate; BRONJ; Bone turnover; Bone scan; Bone scintigraphy; Pathogenesis
Keywords: ALP; alkaline phosphatase; BP; bisphosphonate; FPPS; farnesyl pyrophosphate synthase; Irf8; interferon regulatory factor 8; MafB; V-maf musculoaponeurotic fibrosarcoma oncogene homolog B; MFI; median fluorescence intensity; ONJ; osteonecrosis of the jaw;
Keywords: EHR; electronic health records; EDR; electronic dental records; NDPBRN; National Dental Practice-based Research Network; NIDCR; National Institute of Dental and Craniofacial Research; PBRN; practice-based research network; EMR; electronic medical records;
A comparative study of quality of life, functional and bone outcomes in osteogenesis imperfecta with bisphosphonate therapy initiated in childhood or adulthood
Keywords: BMD; bone mineral density; DXA; dual-energy X-ray absorptiometry; IPAQ; international physical activity questionnaire; IQR; interquartile range; LS; lumbar spine; MET; metabolic equivalent (MET, multiples of resting energy expenditure) system; OI; osteoge
Osteogenesis imperfecta - A clinical update
Keywords: OI; osteogenesis imperfecta; COL1A1; a1 chain of type 1 collagen; COL1A2; a2 chain of type 1 collagen; CNS; central nervous system; aBMD; areal bone mineral density; LS; lumbar spine; BPs; bisphosphonates; RANKL; receptor activator of the nuclear factor k
Osteonecrosis of the jaw in patients treated with denosumab: A multicenter case series
Keywords: Denosumab; Jaw osteonecrosis; MRONJ; ARONJ; DRONJ; ONJ;
Original ResearchDenosumab in advanced/unresectable giant-cell tumour of bone (GCTB): For how long?
Keywords: Giant-cell tumour of the bone; Denosumab; Receptor activator of nuclear factor κB ligand; GCTB; ONJ;
Osteonecrosis of the jaws (ONJ) in mice after extraction of teeth with periradicular disease
Keywords: ONJ; Zoledronic acid; OPG-Fc, extraction; Dental disease;
Spontaneous osteonecrosis of the jaws in the maxilla of mice on antiresorptive treatment: A novel ONJ mouse model
Keywords: Osteonecrosis of the jaw; ONJ; Antiresorptives; Bisphosphonates; Alveolar bone; Osteoclasts
Long-term success of surgery in bisphosphonate-related osteonecrosis of the jaws (BRONJs)
Keywords: BRONJ; Bisphosphonates; ONJ; Osteonecrosis of the jaw; Treatment outcome;
Successful surgical management of osteonecrosis of the jaw due to RANK-ligand inhibitor treatment using fluorescence guided bone resection
Keywords: Fluorescence guided bone resection; Denosumab; Jaw osteonecrosis; ONJ; Drug induced necrosis; Treatment;
Oral care and the use of bone-targeted agents in patients with metastatic cancers: A practical guide for dental surgeons and oncologists
Keywords: Bone metastasis; Bisphosphonate; ONJ; Bone targeted agent
Bisphosphonate-related osteonecrosis of the jaws – Characteristics, risk factors, clinical features, localization and impact on oncological treatment
Keywords: Osteonecrosis of the jaw; Bisphosphonates; ONJ; BRONJ; Risk factors; Clinical features; Localization
Antiresorptives and Osteonecrosis of the Jaw
Keywords: Bisphosphonates; denosumab; osteoporosis; osteonecrosis; ONJ; teriparatide; osteoclast;
Bisphosphonate related osteonecrosis of the jaw - Manifestation in a microvascular iliac bone flap
Keywords: Osteonecrosis; Necrosis; Bisphosphonate; BRONJ; BP-ONJ; ONJ; BONJ; Bone graft; Mandibula reconstruction; Osseous microvascular reconstruction;
Osteoporosis and bisphosphonates-related osteonecrosis of the jaw: Not just a sporadic coincidence – a multi-centre study
Keywords: Bisphosphonate; Bisphosphonate-related osteonecrosis of the jaw; BRONJ; Osteoporosis; Osteonecrosis; Necrosis; ONJ; Oral
Mechanotransduction activates α5β1 integrin and PI3K/Akt signaling pathways in mandibular osteoblasts
Keywords: LIPUS; low intensity pulsed ultrasound; ALP; alkaline phosphatase; FGF23; fibroblast growth factor 23; RANKL; Receptor Activator of Nuclear factor κ-B Ligand; Wnt; Wingless-type MMTV integration site; ONJ; osteonecrosis of the jaw; Mandible; Remodeling;
Safety of bisphosphonates
Keywords: Bisphosphonates; Subtrochanteric fractures; ONJ; Cancer; Atrial fibrillation;
Scintigraphic evaluation of mandibular bone turnover in patients with solid tumors receiving zoledronic acid
Keywords: Zoledronic acid; Bisphosphonate; ONJ; Mandible; Bone turnover; Scintigraphy
Adverse Effects of Bisphosphonates: Implications for Osteoporosis Management
Keywords: BMD; bone mineral density; CTX; carboxy-terminal collagen crosslinks; FDA; Food and Drug Administration; FRAX; fracture risk assessment; GI; gastrointestinal; IV; intravenous; ONJ; osteonecrosis of the jaw;
“Bis-phossy jaws” – High and low risk factors for bisphosphonate-induced osteonecrosis of the jaw
Keywords: bisphosphonates; osteonecrosis; ONJ; osteomyelitis; jaw necrosis; bone infection; Zoledronate; Pamidronate
Bisphosphonates: Mechanism of Action and Role in Clinical Practice
Keywords: ATP; adenosine triphosphate; BMD; bone mineral density; DXA; dual-energy x-ray absorptiometry; FDA; Food and Drug Administration; GIO; glucocorticoid-induced osteoporosis; HORIZON; Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly; IV
Osteonecrosis of the jaw. A newly emerging site-specific osseous pathology in patients with cancer treated with bisphosphonates. Report of five cases and review of the literature
Keywords: Osteonecrosis; Jaw; ONJ; Cancer metastasis; Bisphosphonates; Mandible
Pathophysiology, risk factors and management of bisphosphonate-associated osteonecrosis of the jaw: Is there a diverse relationship of amino- and non-aminobisphosphonates?
Keywords: Aminobisphosphonates; Non-aminobisphosphonates; Osteonecrosis of the jaw; ONJ; Pathophysiology; Risk factors; Management; Clodronate
Primary Surgical Therapy for Osteonecrosis of the Jaw Secondary to Bisphosphonate Therapy
Keywords: BPT; bisphosphonate therapy; IV; intravenous; ONJ; osteonecrosis of the jaw;
Mayo Clinic Consensus Statement for the Use of Bisphosphonates in Multiple Myeloma
Keywords: ASCO; American Society of Clinical Oncology; MM; multiple myeloma; ONJ; osteonecrosis of the jaw; SRE; skeletal-related event;